IHC of paraffin-embedded Adenocarcinoma of Human endometrium tissue using anti-HARS2 mouse monoclonal antibody.
IHC of paraffin-embedded Human endometrium tissue using anti-HARS2 mouse monoclonal antibody.
IHC of paraffin-embedded Human tonsil using anti-HARS2 mouse monoclonal antibody.
IHC of paraffin-embedded Human lymphoma tissue using anti-HARS2 mouse monoclonal antibody.
IHC of paraffin-embedded Carcinoma of Human bladder tissue using anti-HARS2 mouse monoclonal antibody.
IHC of paraffin-embedded Human prostate tissue using anti-HARS2 mouse monoclonal antibody.
IHC of paraffin-embedded Adenocarcinoma of Human ovary tissue using anti-HARS2 mouse monoclonal antibody.
IHC of paraffin-embedded Adenocarcinoma of Human breast tissue using anti-HARS2 mouse monoclonal antibody.
IHC of paraffin-embedded Human breast tissue using anti-HARS2 mouse monoclonal antibody.
IHC of paraffin-embedded Human pancreas tissue using anti-HARS2 mouse monoclonal antibody.
IHC of paraffin-embedded Carcinoma of Human lung tissue using anti-HARS2 mouse monoclonal antibody.
IHC of paraffin-embedded Human lung tissue using anti-HARS2 mouse monoclonal antibody.
IHC of paraffin-embedded Human colon tissue using anti-HARS2 mouse monoclonal antibody.
HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY HARS2 (Right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-HARS2.
HEK293T cells transfected with either overexpress plasmid (Red) or empty vector control plasmid (Blue) were immunostained by anti-HARS2 antibody, and then analyzed by flow cytometry.